Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-SEC Filing-SEC Filing
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine part...
https://www.bloomberg.com/news/articles/2025-11-13/pfizer-looks-to-sell-stake-in-pandemic-vaccine-partner-biontech
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...
UBS analyst David Dai maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $115 to $117.
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...
BioNTech (NASDAQ:BNTX) raises FY2025 sales outlook from $1.787 billion-$2.314 billion to $3.040 billion-$3.274 billion.
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.75 by 1...
